Pith. sign in

REVIEW 4 major objections 4 minor 19 references

Refining Focus in AI for Lung Cancer: Comparing Lesion-Centric and Chest-Region Models with Performance Insights from Internal and External Validation

T0 review · 4 major / 4 minor · reviewed 2026-08-12 · deepseek-v4-flash

Challenge this review Re-run · record.json Download PDF Read on arXiv ↗ Review JSON

Pith's one-line read Lesion-level models outperform chest-region models for lung cancer classification on both an internal test set and two external CT cohorts, with the largest difference on LUNA16 (AUC 0.90 versus 0.63).

desk verdict Good question, weak evidence: the external validation may be contaminated by pretraining on the same datasets, and the internal comparison is not statistically supported, so the superiority claim is not backed by the data as reported. read the letter →

arxiv 2411.16823 v1 pith:SVAASX5D submitted 2024-11-25 eess.IV

Fakrul Islam Tushar This is my paper · ORCID
classification eess.IV
keywords lungcancerCTscreeninglesion-levelmodelchest-regionAUC-ROCexternalvalidationsubgroupanalysisGrad-CAM
verification ladder T0 review T1 audit T2 compute T3 formal

The pith

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The reading

The paper asks whether an AI lung-cancer classifier should look at the nodule alone or at the broader chest region, and it answers with a head-to-head comparison of two models trained on the same data. The lesion-level model, built on 64×64×64 nodule-centered patches, beats the chest-region model, built on 512×512×8 thoracic volumes, on every dataset tested: AUC 0.71 versus 0.68 internally, 0.90 versus 0.63 on LUNA16, and 0.81 versus 0.71 on NLST. Subgroup analyses show the lesion-level advantage persists across sex, smoking status, key histologies, and CT manufacturers, and gradient heatmaps show it concentrates on the nodule while the chest-region model spreads its attention. A sympathetic reader would take this as evidence that nodule-centric input is the right inductive bias for malignancy classification, with practical payoff in external generalizability and interpretability.

What carries the argument

The comparison is carried by two 3D convolutional models that share training data, preprocessing, optimizer, and loss but differ in input focus. The lesion-level model uses ResNet50-SWS++, a ResNet-50 variant pretrained with Strategic WarmStart++, applied to 64×64×64 patches centered on each nodule. The chest-region model takes 512×512×8 volumes spanning the thorax and is initialized from the weights of a false-positive-reduction model from the same prior work. These inputs are the central object of the paper: the identity of everything else is held fixed, so differences in AUC-ROC, subgroup behavior, probability distributions, and Grad-CAM localization are attributed to lesion-centric versus chest-region focus.

What would settle it

Check the training data behind the pretrained ResNet50-SWS++ and false-positive-reduction weights: if any LUNA16 or NLST scans appear there, rerun both models trained from scratch on DLND24 only and compare the resulting external AUCs; the reported 0.90 versus 0.63 LUNA16 gap should shrink or disappear.

Watch

Extended reading notes

Core claim

The central claim is that lesion-level models demonstrate superior classification performance, especially for external datasets and challenging subgroups. On DLND24, the internal held-out test set, the lesion-level model reaches AUC 0.71 (95% CI 0.61–0.81) versus 0.68 (0.57–0.77) for the chest-region model. The gap widens externally: on LUNA16, AUC 0.90 (0.87–0.92) versus 0.63 (0.58–0.67), and on NLST, AUC 0.81 (0.79–0.82) versus 0.71 (0.69–0.72). The paper further argues that the lesion-level model's predicted probabilities separate benign from malignant cases cleanly, while the chest-region model's distributions overlap, and that Grad-CAM-family visualizations localize to nodules only for the lesion-level model. The intended conclusion is that nodule-centric models are better suited for precision lung cancer diagnostics.

Load-bearing premise

The central comparison holds only if LUNA16 and NLST were truly external to all stages of model development, including the earlier training of the starting weights, and the paper does not show that this was the case.

Editorial extensions

If this is right

  • If the lesion-level advantage holds, screening AI can be built around a detector-plus-patch-classifier design, avoiding the need for full-chest context in malignancy classification.
  • The external results imply that nodule-centric models transfer across scanners and protocols better than chest-region models, since the largest advantage appears on LUNA16 rather than on the institutional test set.
  • Subgroup results imply that lesion-level models reduce performance gaps in difficult cases such as adenocarcinoma and across different CT manufacturers, supporting their use in more diverse populations.
  • The interpretability evidence implies that clinicians can check the model's decision by looking at whether its heatmap falls on the nodule, which is closer to a radiologist's own workflow.

Reading between the lines

Editorial extensions of the paper, not claims the author makes directly.

  • The paper does not disclose what data were used for the prior pretraining of ResNet50-SWS++ and the false-positive-reduction weights; if LUNA16 or NLST contributed to those stages, the reported external AUCs would be inflated and the central conclusion would need to be retested with pretraining restricted to DLND24.
  • The LUNA16 gap, 0.90 versus 0.63, is large enough to suspect it is not only about input focus: the two datasets define and label nodules differently, and no explicit label harmonization is described, so a matched-label reanalysis is a natural test.
  • One practical extension the paper leaves implicit is a hybrid pipeline where a nodule detector narrows the chest volume and the lesion-level classifier judges the detected patches; this would make the lesion-level approach applicable to whole-CT screening rather than to pre-annotated nodules.
Share X Bluesky LinkedIn Reddit HN

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, and a circularity audit.

Referee Report

4 major / 4 minor

Summary. The paper compares two 3D CNN models for lung cancer classification from chest CT: a lesion-level model that takes 64x64x64 nodule-centric patches and a chest-region model that takes 512x512x8 chest volumes. Both models are trained on an internal dataset (DLND24) and evaluated on the same internal test set plus two external datasets, LUNA16 and NLST. The authors report higher AUC-ROC for the lesion-level model in all settings (internal 0.71 vs 0.68; LUNA16 0.90 vs 0.63; NLST 0.81 vs 0.71), supplemented by subgroup analyses and gradient-based visualizations. The conclusion is that lesion-level models demonstrate superior classification performance, especially for external datasets.

Significance. If the comparison were valid, the finding that nodule-centric input representations outperform whole-chest input representations would provide a practical design guideline for lung cancer screening AI. The attempt to include external validation and subgroup analyses is commendable. However, the central claim rests on external AUC values that may be inflated by data contamination: both models use pretrained weights from a prior study [7] that, according to the manuscript, used LUNA16 and NLST. The internal AUC difference is not statistically significant, so the external results carry the entire argument. The paper does not provide code or sufficient training details, and there are major inconsistencies in the reported dataset sizes. These issues prevent the paper from making a reliable contribution as it stands.

major comments (4)
  1. [Materials and Methods, AI Model Development; Patient Data and Imaging Datasets] The external validation is potentially contaminated. The lesion-level model uses ResNet50-SWS++ weights pretrained in [7], and the chest-region model uses false-positive-reduction weights from [7]. The manuscript states that LUNA16 and NLST were 'used in an earlier study [7, 11]' but never discloses whether the pretraining in [7] included these datasets. If they did, the external test sets are not independent, and the reported external AUCs (LUNA16 0.90, NLST 0.81) would be inflated by data leakage. This is load-bearing because the paper's primary conclusion—'Lesion-level models demonstrate superior classification performance, especially for external datasets'—depends entirely on those external numbers. The authors must clarify the composition of the pretraining data, and if the external datasets were used, must retrain without them or use genuinely held-out external data.
  2. [Results, Overall Performance] The internal AUC difference is not statistically established. The Methods section states that DeLong's test was used, but no p-values are reported anywhere in the Results. The internal lesion-level AUC of 0.71 (95% CI 0.61–0.81) and chest-region AUC of 0.68 (95% CI 0.57–0.77) have heavily overlapping confidence intervals, so the claim of 'consistently outperformed' is not supported for the internal data alone. Without a DeLong p-value or some equivalent statistical test, the internal comparison is inconclusive.
  3. [Table 1 and Figure 1] The dataset counts are internally inconsistent. The Methods section states LUNA16 includes 888 CT scans; Table 1 reports 601 patients for LUNA16; and Figure 1 reports LUNA16 N=433 with 677 nodules. Similarly, NLST is given as 969 patients in Table 1 and Figure 1, but Figure 1 reports 3128 nodules, while Table 1's nodule-level counts sum to 1192 malignant nodules with no benign count provided. The internal dataset is called DLND24 in the abstract but appears as 'Duke Lung Cancer Screening Dataset' in Table 1 and as DLCSD in the data availability statement. These discrepancies undermine confidence in the reported evaluation and must be reconciled before any further consideration.
  4. [Results, Subgroup Analysis] The subgroup analysis claims are not supported by reported statistics. The text states that the lesion-level model showed 'significant advantages' for current smokers, adenocarcinoma, and certain CT manufacturers, but no p-values, confidence intervals, or multiple-comparison corrections are reported for these subgroups. Figure 3 and Figure 4 show error bars, but the corresponding numerical values and test statistics are absent from the text. Without this information, the subgroup conclusions are unverifiable.
minor comments (4)
  1. [Evaluation Metrics] The phrase 'Area under the curve-curve-receiver operating Characteristic (AUC-ROC)' contains a typo; it should be 'Area under the receiver operating characteristic curve.'
  2. [References] References [5] and [19] appear to be the same work (the SPIE Medical Imaging 2022 paper on co-occurring diseases), cited twice with different formatting. This should be consolidated.
  3. [AI Model Development] Training details are insufficient for reproducibility: no learning rate, batch size, number of epochs, data augmentation, or hardware specifications are provided. The claim that models were 'trained end-to-end' is not enough.
  4. [Discussion and Figure 6] The interpretability analysis is used as supporting evidence for the model comparison, but the authors themselves note in the limitations that quantitative metrics for interpretability are needed. The visualizations should be treated as illustrative, not as a standalone confirmation of superiority.

Circularity Check

1 steps flagged · score 4.0 of 10

External validation may be in-sample: both models are initialized from the author's prior-work weights [7], and the same prior work [7] is cited as the source of the 'external' LUNA16 and NLST datasets, with no stated exclusion of those sets from pretraining.

  1. fitted input called prediction [Materials and Methods, 'Patient Data and Imaging Datasets' and 'AI Model Development']
    "two external datasets, LUNA16 and NLST used in an earlier study [7, 11] ... The lesion-level model employed the ResNet50-SWS++, an architecture introduced in an earlier study, which utilized Strategic WarmStart++ (SWS++) pretraining [7]. The chest-region model leveraged the pre-trained weights of a false positive reduction model, as detailed in prior work [7]."

    The paper's headline external result (LUNA16 AUC 0.90 vs 0.63; NLST 0.81 vs 0.71) is presented as independent validation, but the models are not trained from scratch on DLND24 alone: their initial parameters come from [7], and the 'external' datasets are described as 'used in an earlier study [7]'. A false-positive-reduction model, the initialization source for the chest-region model, is conventionally trained on LUNA16-style nodule candidates, and the paper nowhere states that the [7] pretraining excluded LUNA16 and NLST. If those datasets appeared in the [7] fitting stages, the reported external AUCs are in-sample evaluations of previously fitted weights, i.e., fitted parameters renamed as predictions, not an out-of-sample test of the present comparison.

full rationale

The central claim that lesion-level models are superior 'especially for external datasets' is carried almost entirely by the external AUCs, because the internal DLND24 difference (0.71 vs 0.68) has overlapping confidence intervals. The derivation chain for the external numbers is: take weights from the author's prior work [7], then evaluate on datasets that the same sentence identifies as 'used in an earlier study [7]'. The paper never reports whether the SWS++ pretraining or the false-positive-reduction pretraining saw the LUNA16/NLST test sets, so the independence assumption that makes these datasets 'external' is load-bearing and unverified. This is a fitted-input-called-prediction pattern rather than an equation-level equivalence, and because a genuinely from-scratch DLND24 training component exists, I score the circularity burden as moderate (4), not 6-8. The dataset-count inconsistencies (LUNA16: 888 in the abstract, 601 in Table 1, 433 and 677 nodules in Figure 1) further weaken confidence in the evaluation but are data-handling/correctness concerns, not circular steps. No other reduction-by-construction or renamed-known-result pattern was identifiable from the manuscript text alone.

Assumptions & free parameters 0 free parameters · 4 assumptions · 0 invented entities

The paper introduces no new theoretical entities or hand-fitted constants. Its central claim rests on domain assumptions about label accuracy and on the undisclosed independence of the pretraining data from the external test sets. If the pretraining in [7] used LUNA16 or NLST, the external performance numbers would be invalid.

assumptions (4)
  • domain assumption DLND24 benign/malignant labels accurately reflect clinical truth
    The internal model training and validation rely on these labels; no pathology confirmation details are provided, only the cohort table.
  • domain assumption The pretrained weights from [7] do not include LUNA16 or NLST in a way that leaks into external testing
    The paper does not disclose the pretraining data; if false, the external validation is invalid.
  • domain assumption LUNA16 RVAMI and NLST cancer labels are reliable proxy labels for malignancy
    LUNA16 uses LIDC-IDRI radiologist malignancy scores, not pathology; NLST uses screen-detected cancer outcomes. These label conventions differ from DLND24.
  • standard math DeLong's test and bootstrap confidence intervals are correctly applied
    No p-values are reported and multiple nodules per patient may violate independence; the paper does not describe a clustered DeLong test.

how reviews work

0 comments
Cite this review

Pith. "Pith review of Refining Focus in AI for Lung Cancer: Comparing Lesion-Centric and Chest-Region Models with Performance Insights from Internal and External Validation." pith.science (2026). https://pith.science/paper/SVAASX5D

@misc{pith2026241116823,
  author       = {Pith},
  title        = {Pith review of: Refining Focus in AI for Lung Cancer: Comparing Lesion-Centric and Chest-Region Models with Performance Insights from Internal and External Validation},
  year         = {2026},
  howpublished = {\url{https://pith.science/paper/SVAASX5D}},
  note         = {Machine review of arXiv:2411.16823}
}
read the original abstract

Background: AI-based classification models are essential for improving lung cancer diagnosis. However, the relative performance of lesion-level versus chest-region models in internal and external datasets remains unclear. Purpose: This study evaluates the performance of lesion-level and chest-region models for lung cancer classification, comparing their effectiveness across internal Duke Lung Nodule Dataset 2024 (DLND24) and external (LUNA16, NLST) datasets, with a focus on subgroup analyses by demographics, histology, and imaging characteristics. Materials and Methods: Two AI models were trained: one using lesion-centric patches (64,64,64) and the other using chest-region patches (512,512,8). Internal validation was conducted on DLND24, while external validation utilized LUNA16 and NLST datasets. The models performances were assessed using AUC-ROC, with subgroup analyses for demographic, clinical, and imaging factors. Statistical comparisons were performed using DeLongs test. Gradient-based visualizations and probability distribution were further used for analysis. Results: The lesion-level model consistently outperformed the chest-region model across datasets. In internal validation, the lesion-level model achieved an AUC of 0.71(CI: 0.61-0.81), compared to 0.68(0.57-0.77) for the chest-region model. External validation showed similar trends, with AUCs of 0.90(0.87-0.92) and 0.81(0.79-0.82) on LUNA16 and NLST, respectively. Subgroup analyses revealed significant advantages for lesion-level models in certain histological subtypes (adenocarcinoma) and imaging conditions (CT manufacturers). Conclusion: Lesion-level models demonstrate superior classification performance, especially for external datasets and challenging subgroups, suggesting their clinical utility for precision lung cancer diagnostics.

Figures

Figures reproduced from arXiv: 2411.16823 by the authors.

Figure 1
Figure 1. Overview of the study design and methodology for evaluating lesion-level and chest-region models for lung cancer classification. The analysis utilized three datasets: DLND24 (internal dataset, N=1613; n=2487 nodules), LUNA16 (external dataset, N=433; n=677 nodules), and NLST (external dataset, N=969; n=3128 nodules). Both models were trained on DLND24 and evaluated on internal and external test sets. The chest-regio… view at source ↗
Figure 2
Figure 2. Performance of Lesion-Level and Chest-Region Models Across Datasets. (a) Internal dataset performance evaluated on DLND24, showing AUC-ROC comparisons for lesion-level and chest-region models. (b) External dataset performance on LUNA16, highlighting differences in model classification accuracy. (c) External dataset performance on NLST, illustrating generalizability of both models across a large screening dataset [P… view at source ↗

Discussion (0). Continue with ORCID to comment.

Reference graph

Works this paper leans on

19 extracted references · 13 canonical work pages

  1. [7]

    AI in Lung Health: Benchmarking Detection and Diagnostic Models Across Multiple CT Scan Datasets,

    F. I. Tushar et al. , "AI in Lung Health: Benchmarking Detection and Diagnostic Models Across Multiple CT Scan Datasets," arXiv preprint arXiv:2405.04605, 2024

    arXiv 2024

  2. [1]

    Reduced Lung -Cancer Mortality with Low -Dose Computed Tomographic Screening,

    "Reduced Lung -Cancer Mortality with Low -Dose Computed Tomographic Screening," New England Journal of Medicine, vol. 365, no. 5, pp. 395 -409, 2011, doi: 10.1056/nejmoa1102873

    doi:10.1056/nejmoa1102873 2011

  3. [2]

    Reduced Lung -Cancer Mortality with Volume CT Screening in a Randomized Trial,

    H. J. De Koning et al., "Reduced Lung -Cancer Mortality with Volume CT Screening in a Randomized Trial," New England Journal of Medicine, vol. 382, no. 6, pp. 503-513, 2020, doi: 10.1056/nejmoa1911793

    work page doi:10.1056/nejmoa1911793 2020

  4. [3]

    Cancer statistics for the year 2020: An overview,

    J. Ferlay et al., "Cancer statistics for the year 2020: An overview," International Journal of Cancer, vol. 149, no. 4, pp. 778-789, 2021, doi: 10.1002/ijc.33588

    doi:10.1002/ijc.33588 2020

  5. [4]

    Lung Nodule Management in Low -Dose CT Screening for Lung Cancer: Lessons from the NELSON Trial,

    D. Zhong et al., "Lung Nodule Management in Low -Dose CT Screening for Lung Cancer: Lessons from the NELSON Trial," Radiology, vol. 313, no. 1, p. e240535, 2024

    work page 2024

  6. [5]

    F. I. Tushar, V. D'Anniballe, G. Rubin, E. Samei, and J. Lo, Co-occurring diseases heavily influence the performance of weakly supervised learning models for classification of chest CT (SPIE Medical Imaging). SPIE, 2022

    work page 2022

  7. [6]

    Virtual Lung Screening Trial (VLST): An In Silico Study Inspired by the National Lung Screening Trial for Lung Cancer Detection

    F. I. Tushar et al., "Virtual Lung Screening Trial (VLST): An In Silico Replica of the National Lung Screening Trial for Lung Cancer Detection," arXiv preprint arXiv:2404.11221, 2024

    work page Pith review arXiv 2024

  8. [8]

    Sybil: A Validated Deep Learning Model to Predict Future Lung Cancer Risk From a Single Low-Dose Chest Computed Tomography,

    P. G. Mikhael et al., "Sybil: A Validated Deep Learning Model to Predict Future Lung Cancer Risk From a Single Low-Dose Chest Computed Tomography," Journal of Clinical Oncology, vol. 41, no. 12, pp. 2191-2200, 2023, doi: 10.1200/jco.22.01345

    work page doi:10.1200/jco.22.01345 2023

Show all 19 references
  1. [9]

    Foundation model for cancer imaging biomarkers,

    S. Pai et al. , "Foundation model for cancer imaging biomarkers," Nature machine intelligence, pp. 1-14, 2024

    2024

  2. [10]

    End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography,

    D. Ardila et al., "End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography," Nature medicine, vol. 25, no. 6, pp. 954-961, 2019

    2019

  3. [11]

    A. Wang, F. I. Tushar, M. R. Harowicz, K. J. Lafata, T. D. Tailor, and J. Y. Lo. Duke Lung Nodule Dataset 2024, Zenodo, doi: 10.5281/zenodo.10782891

    2024 doi

  4. [12]

    Validation, comparison, and combination of algorithms for automatic detection of pulmonary nodules in computed tomography images: The LUNA16 challenge,

    A. A. A. Setio et al., "Validation, comparison, and combination of algorithms for automatic detection of pulmonary nodules in computed tomography images: The LUNA16 challenge," Medical Image Analysis, vol. 42, pp. 1 -13, 2017, doi: 10.1016/j.media.2017.06.015

    2017 doi

  5. [13]

    Grad -cam: Visual explanations from deep networks via gradient -based localization,

    R. R. Selvaraju, M. Cogswell, A. Das, R. Vedantam, D. Parikh, and D. Batra, "Grad -cam: Visual explanations from deep networks via gradient -based localization," in Proceedings of the IEEE international conference on computer vision, 2017, pp. 618-626

    2017

  6. [14]

    Smoothgrad: removing noise by adding noise,

    D. Smilkov, N. Thorat, B. Kim, F. Viégas, and M. Wattenberg, "Smoothgrad: removing noise by adding noise," arXiv preprint arXiv:1706.03825, 2017

    2017 arXiv

  7. [15]

    pROC: an open-source package for R and S+ to analyze and compare ROC curves,

    X. Robin et al., "pROC: an open-source package for R and S+ to analyze and compare ROC curves," BMC Bioinformatics, vol. 12, no. 1, p. 77, 2011/03/17 2011, doi: /10.1186/1471- 2105-12-77

    2011 doi

  8. [16]

    A foundation model utilizing chest ct volumes and radiology reports for supervised-level zero-shot detection of abnormalities,

    I. E. Hamamci et al., "A foundation model utilizing chest ct volumes and radiology reports for supervised-level zero-shot detection of abnormalities," CoRR, 2024

    2024

  9. [17]

    Classification of Multiple Diseases on Body CT Scans Using Weakly Supervised Deep Learning,

    F. I. Tushar et al. , "Classification of Multiple Diseases on Body CT Scans Using Weakly Supervised Deep Learning," Radiol Artif Intell, vol. 4, no. 1, p. e210026, Jan 2022, doi: 10.1148/ryai.210026

    2022 doi

  10. [18]

    Machine-Learning-Based Multiple Abnormality Prediction with Large-Scale Chest Computed Tomography Volumes,

    Rachel Lea Draelos et al., "Machine-Learning-Based Multiple Abnormality Prediction with Large-Scale Chest Computed Tomography Volumes," Med Image Anal, vol. 67, p. 101857, 2020 2021

    2020

  11. [19]

    Co -occurring Diseases Heavily influence the Performance of Weakly Supervised Learning Models for Classification of Chest CT,

    F. I. Tushar, V. M. D’Anniballe, G. D. Rubin, E. Samei, and J. Y. Lo, "Co -occurring Diseases Heavily influence the Performance of Weakly Supervised Learning Models for Classification of Chest CT," presented at the Medical Imaging 2022: Computer -Aided Diagnosis, 2020

    2022

Pith tools

Reviewed August 12, 2026 · model on record in the stance chip above.